1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
Bone Biologics Corporation

Bone Biologics Corporation

BBLGW
Bone Biologics CorporationUS flagNASDAQ Capital Market
16.87
USD
+2.72
- -
30.29MMarket Cap
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-14
-26
-7
-4
-3
-2
-2
-1
-9
-4
-3
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Working Capital
- -
-1
-1
- -
-9
-1
-14
7
6
3
3
5
5
LT Debt
4
5
8
8
- -
11
- -
- -
- -
- -
- -
- -
- -
Total Equity
-4
-6
-8
-8
-9
-12
-14
7
6
3
3
5
5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
2
2
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
6
6
5
Cash, Cash Equivalents & STI
6
5
5
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-3.11%
-26.89%
54.37%
Free Cash Flow
42.21%
90.88%
-34.76%
Net Income, GAAP
31.19%
80.95%
-24.4%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Jeffrey Frelick
Full Time Employees
2
Sector
Healthcare
Industry
Medical - Devices
Address
2 Burlington Woods Drive Burlington MA United States of America 01803
IPO Date
Oct 13, 2021
CIK
0001419554
Website
bonebiologics.com
Similar Companies
PHC Holdings Corporation (6523.T)
Vascular Solutions LLC (VASC)
DexCom, Inc. (DXCM)
Stille AB (STIL.ST)
Ion Beam Applications S.A. (IBAB.BR)
TruScreen Group Limited (TRU.AX)
Business
Bone Biologics Corporation, a medical device company focused on developing orthobiologic products for bone regeneration in spinal fusion procedures, offers its lead product candidate NB1, which combines the recombinant human NELL-1 (rhNELL-1) protein with demineralized bone matrix (DBM) to provide rapid, specific, and guided control over bone formation; the NELL-1/DBM fusion device for lumbar spinal fusion; and the NELL-1 platform technology applicable to spinal, orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine applications. Founded in 2004 and headquartered in Burlington, Massachusetts, the company licenses NELL-1 technology from the UCLA Technology Development Group and targets spine surgeons treating patients with skeletal bone defects, degenerative disc disease, and hard-to-heal bones in markets including the United States and Australia. Recent developments include dosing the first patients in a multicenter pilot clinical trial of NB1 for transforaminal lumbar interbody fusion in June 2024, with enrollment expected to complete by year-end 2025; extending NB1 protein shelf life to 18 months and advancing toward 24 months; completing a $5.0 million public offering in June 2025 to fund operations into Q2 2026; and securing approximately $2.1 million in gross proceeds from warrant exercises in 2024 and 2025 for clinical trials, patent expansion, and working capital.

Company News

APIChat

  • defenseworld.net

    Bone Biologics (NASDAQ:BBLGW) Stock Price Down 25.9% – Time to Sell?

  • defenseworld.net

    Bone Biologics (NASDAQ:BBLGW) Stock Price Down 0.3% – What’s Next?

  • defenseworld.net

    Bone Biologics (NASDAQ:BBLGW) Trading Up 2.2% – Should You Buy?

  • defenseworld.net

    Bone Biologics (NASDAQ:BBLGW) Trading Up 29.2% – Here’s Why